α_(1)肾上腺素能受体阻滞剂降低肝硬化门脉高压的实验研究  

Experimental study of reducing cirrhotic portal hypertension byα_(1) adrenergic receptor blocker

作　　者：修爱媛 王思宁 丁茜 王广川[1,2] 张春清 Xiu Aiyuan;Wang Sining;Ding Qian;Wang Guangchuan;Zhang Chunqing(Department of Gastroenterology,Shandong Provincial Hospital Affiliated to Shandong University,Jinan 250021,China;Department of Gastroenterology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)

机构地区：[1]山东大学附属省立医院消化内科,济南250021 [2]山东第一医科大学附属省立医院消化内科,济南250021

出　　处：《中华消化病与影像杂志（电子版）》2021年第3期117-120,共4页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

基　　金：国家自然科学基金(81970533)。

摘　　要：目的探究α_(1)肾上腺素能受体(α_(1)AR)阻滞剂在降低肝硬化门脉高压中的作用。方法采用随机数字表法将50只小鼠分成5组,肝硬化小鼠造模采用四氯化碳(CCl_(4))造模法,α_(1)AR阻滞剂选用多沙唑嗪。分为5组:橄榄油组;CCl_(4)组;CCl_(4)+多沙唑嗪2.5 mg/(kg·d)组;CCl_(4)+多沙唑嗪5 mg/(kg·d)组;CCl_(4)+多沙唑嗪10 mg/(kg·d)组。干预结束后,进行门静脉压力测定,并进行统计学分析。结果α_(1)AR阻滞剂(多沙唑嗪)可降低肝硬化小鼠的死亡率。与橄榄油组相比,其他4组小鼠的门静脉压力均有明显增高(P均<0.05)。与CCl_(4)组相比,CCl_(4)+多沙唑嗪2.5 mg/(kg·d)组及CCl_(4)+多沙唑嗪5 mg/(kg·d)组的小鼠门静脉压力水平均有降低,但差异均无统计学意义。与CCl_(4)组相比,CCl_(4)+多沙唑嗪10 mg/(kg·d)组的小鼠门静脉压力水平明显降低,差异有统计学意义(P<0.05)。结论α_(1)AR阻滞剂(多沙唑嗪)可抑制肝硬化小鼠门静脉压力升高,降低肝硬化小鼠的死亡率,可能为肝硬化门脉高压的治疗提供新思路。Objective To explore the role ofα_(1) adrenergic receptor(α_(1)AR)blocker in reducing portal hypertension in liver cirrhosis.Methods Fifty mice were divided into 5 groups by random number table method.Carbon tetrachloride(CCl_(4))was used to model liver cirrhosis,and doxazosin was used asα_(1)AR blocker.The mice were grouped into:①olive oil group,②CCl_(4) group,③CCl_(4)+doxazosin 2.5 mg/(kg*day)group,④CCl_(4)+doxazosin 5 mg/(kg*day)group,⑤CCl_(4)+doxazosin 10 mg/(kg*day)group.At the end of the intervention,portal venous pressure was measured and statistically analyzed.Resultsα_(1)AR blocker(doxazosin)could reduce the mortality of mice with liver cirrhosis.Compared with the olive oil group,the portal venous pressures of the mice in the other four groups were significantly higher(all P<0.05).Compared with the CCl_(4) group,the portal venous pressure levels of mice in the CCl_(4)+doxazosin 2.5 mg/(kg*day)group and CCl_(4)+doxazosin 5 mg/(kg*day)group were statistically reduced,but there were no statistically significant differences(both P>0.05).Compared with the CCl_(4) group,the portal pressure level of mice in the CCl_(4)+doxazosin 10 mg/(kg*day)group was significantly reduced,and there was a statistically significant difference(P<0.05).Conclusionα_(1)AR blocker(doxazosin)can inhibit the increase of portal venous pressure in cirrhotic mice and reduce the mortality of cirrhotic mice,which may provide new ideas for the treatment of portal hypertension in cirrhosis.

关 键 词：门脉高压症 肝硬化 α_(1)AR阻滞剂 

分 类 号：R57[医药卫生—消化系统]